About

Mechanical circulatory support has emerged as an important therapy for advanced heart failure. These devices significantly improve survival and quality of life and should be considered in every patient with end-stage heart failure with reduced ejection fraction who has no other life-limiting diseases.

Devices, such as implantable cardioverter-defibrillators (ICDs), and novel pacing technologies, including cardiac resynchronisation therapy (CRT), have helped to complement goal-directed medical therapy and positively impact prognosis in these patients, as demonstrated in multiple high-quality clinical trials.

Articles

Highlights from the ESC Congress 2021

Published:

13 May 2022

Citation:

European Cardiology Review 2022;17:e12.

Hemodynamic Monitoring in the Critical Care Setting

Published:

28 April 2022

Citation:

US Cardiology Review 2022;16:e12.

Utility of HeartLogic in Heart Failure

Published:

21 April 2022

Citation:

Cardiac Failure Review 2022;8:e13.

Cardiogenic Shock: Past, Present, and Future Outlook

Published:

10 February 2022

Citation:

US Cardiology Review 2022;16:e03.